🔴 SAB Biotherapeutics is trading 14% down in pre-market — with no clear company-specific catalyst identified

SAB Biotherapeutics is trading at $2.40, down 13.98% in pre-market on October 27, with no clear company-specific catalyst identified. - Shares closed at $2.79 on October 26. - Recent company news included an October 14 conference announcement and October 13 FDA Fast Track news; neither was a new October 27 catalyst. - Broader market indicators were mixed and modest, while pre-market volume information was unavailable.